Business Description
No business description found.
You might also like
Q2 2024 Summary
What went well
- Strong sales growth from new product launches in Japan, specifically the TSUMITAS product targeting younger customers, leading to increased sales and cross-selling opportunities for third sector products.
- Improved U.S. persistency rates, with early signs from initiatives showing positive results; even a 100 basis point improvement is meaningful and contributes to additional net earned premium over time.
- Maintained #1 position in Japan's third sector market despite increased competition, highlighting Aflac's strong customer trust and ability to provide appropriate insurance policies, leading to continued sales growth.
What went wrong
- The new TSUMITAS product in Japan has a lower internal rate of return (IRR) than core third sector products due to significant new business strain associated with higher reserves, relying on reinsurance to achieve acceptable returns, which may pressure profitability.
- Competitors in Japan are entering the third sector market with low-priced products, creating a challenging competitive environment that is "totally different compared with maybe 5 years ago or 10 years ago," potentially impacting Aflac's market share and margins.
- Aflac's strategy of targeting younger customers who may have less disposable income may lead to slower cross-selling opportunities and impact sales growth and immediate profitability in the near term.
Q&A Summary
-
Profitability of TSUMITAS Product
Q: How does TSUMITAS's return compare to third sector products?
A: The TSUMITAS product launched in June has at or higher GAAP margins than our core third sector business. On an IRR basis, though initially lower due to higher reserves, reinsurance brings returns to very attractive levels, similar to our core business. -
U.S. Sales and Guidance
Q: Can you achieve full-year sales guidance despite a light quarter?
A: Despite a 2% sales increase this quarter, we're confident in hitting guidance. We anticipate stronger sales in the second half due to seasonality, new products, and improved productivity. -
Expense Ratio Sustainability
Q: Are low expense ratios in Japan and U.S. sustainable?
A: In Japan, the expense ratio of 17.8% is expected to be at the lower end of the 19%–21% range for the year. In the U.S., expenses may rise due to seasonality, keeping the ratio within the 38%–40% guidance. -
Competition in Japan
Q: How is the competitive environment in Japan evolving?
A: Competition has intensified with new entrants offering low-priced products. However, we focus on providing value, maintaining our position as the #1 seller of third sector products in Japan. -
Net Investment Income in Japan
Q: What drove higher net investment income and is it sustainable?
A: The strong quarter was driven by attractive short rates, tactical portfolio actions, and accelerated deployment in structured private credit. We believe these tailwinds are sustainable into the second half. -
U.S. Persistency Improvement
Q: How much can you improve U.S. persistency?
A: Even a 100 basis points improvement is meaningful. We're focusing on business improvements and beneficial mix shifts toward products with higher persistency. -
U.S. Recruiting Trends
Q: What is the status of U.S. recruiting recovery?
A: Recruiting improved over 10% in Q2. We're emphasizing quality recruiting and better productivity, expecting similar recruitment numbers as last year. -
TSUMITAS Product Rollout
Q: Will TSUMITAS become a larger sales percentage?
A: After an initial sales spike, we expect TSUMITAS sales to level off but continue contributing significantly, aiding cross-selling of third sector products without capping sales due to strong returns. -
Difference from WAYS Sales
Q: How does TSUMITAS differ from previous WAYS sales?
A: TSUMITAS involves more frequent repricing, diligent distribution management, and use of reinsurance to improve IRRs, differentiating it from the significant WAYS sales of 2012–2014.
Key Metrics
Revenue by Segment - in Millions of USD | FY 2013 | Q1 2014 | Q2 2014 | Q3 2014 | Q4 2014 | FY 2014 | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | FY 2015 | Q1 2016 | Q2 2016 | Q3 2016 | Q4 2016 | FY 2016 | Q1 2017 | Q2 2017 | Q3 2017 | Q4 2017 | FY 2017 | Q1 2018 | Q2 2018 | Q3 2018 | Q4 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aflac Japan | 2,790 | 2,710 | 2,660 | 2,504 | 10,664 | 2,473 | 2,447 | 2,378 | ||||||||||||||||||||||||||||||||||||||||||||||
- Net Earned Premiums | 1,428 | 1,425 | 1,419 | 1,403 | 5,675 | 1,475 | 1,455 | 1,459 | ||||||||||||||||||||||||||||||||||||||||||||||
- Net Investment Income | 197 | 203 | 209 | 245 | 854 | 206 | 218 | 210 | ||||||||||||||||||||||||||||||||||||||||||||||
- Other Income | 35 | 35 | 33 | 25 | 128 | 18 | 11 | 15 | ||||||||||||||||||||||||||||||||||||||||||||||
Aflac U.S. | 1,660 | 1,663 | 1,661 | 1,639 | 6,623 | 1,699 | 1,684 | 1,684 | ||||||||||||||||||||||||||||||||||||||||||||||
Other Business Segments | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||
Corporate and Other | 129 | 140 | 115 | 76 | 460 | 247 | 249 | 225 | ||||||||||||||||||||||||||||||||||||||||||||||
Total Adjusted Revenues | 4,579 | 4,513 | 4,436 | 4,219 | 17,747 | 4,419 | 4,380 | 4,287 | ||||||||||||||||||||||||||||||||||||||||||||||
Total Revenues | 4,800 | 5,172 | 4,950 | 3,779 | 18,701 | 5,436 | 5,138 | 2,949 | ||||||||||||||||||||||||||||||||||||||||||||||
Revenue by Geography - in Millions of USD | FY 2013 | Q1 2014 | Q2 2014 | Q3 2014 | Q4 2014 | FY 2014 | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | FY 2015 | Q1 2016 | Q2 2016 | Q3 2016 | Q4 2016 | FY 2016 | Q1 2017 | Q2 2017 | Q3 2017 | Q4 2017 | FY 2017 | Q1 2018 | Q2 2018 | Q3 2018 | Q4 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 |
Aflac Japan | - | - | - | - | 10,664 | 2,473 | 2,447 | 2,378 | ||||||||||||||||||||||||||||||||||||||||||||||
- Net Earned Premiums | - | - | - | - | - | 1,475 | - | - | ||||||||||||||||||||||||||||||||||||||||||||||
- Adjusted Net Investment Income | - | - | - | - | - | 206 | - | - | ||||||||||||||||||||||||||||||||||||||||||||||
- Other Income | - | - | - | - | - | 18 | - | - | ||||||||||||||||||||||||||||||||||||||||||||||
Aflac U.S. | - | - | - | - | 6,623 | 1,699 | 1,684 | 1,684 | ||||||||||||||||||||||||||||||||||||||||||||||
Corporate and Other | - | - | - | - | 460 | 247 | 249 | 225 | ||||||||||||||||||||||||||||||||||||||||||||||
Total Revenue | 4,800 | 5,200 | 5,000 | 2,747 | 17,747 | 5,436 | 5,138 | 2,949 | ||||||||||||||||||||||||||||||||||||||||||||||
KPIs - Metric | FY 2013 | Q1 2014 | Q2 2014 | Q3 2014 | Q4 2014 | FY 2014 | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | FY 2015 | Q1 2016 | Q2 2016 | Q3 2016 | Q4 2016 | FY 2016 | Q1 2017 | Q2 2017 | Q3 2017 | Q4 2017 | FY 2017 | Q1 2018 | Q2 2018 | Q3 2018 | Q4 2018 | FY 2018 | Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | FY 2019 | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | FY 2020 | Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | FY 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | FY 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | FY 2023 | Q1 2024 | Q2 2024 | Q3 2024 |
New Annualized Premium Sales (¥ Billion) | ¥13.2 | ¥16.1 | ¥15.6 | ¥15.8 | - | ¥12.5 | ¥16.8 | ¥17.5 | ||||||||||||||||||||||||||||||||||||||||||||||
New Annualized Premium Sales ($ Million) | $100 | $117 | $108 | $107 | - | $84 | $108 | $117 | ||||||||||||||||||||||||||||||||||||||||||||||
Contributions by Major Insurance Product - Cancer (%) | 59.9 | 67.7 | 65.6 | 62.5 | - | 63.2 | 58.8 | 55.1 | ||||||||||||||||||||||||||||||||||||||||||||||
Contributions by Major Insurance Product - Medical (%) | 20.8 | 17.5 | 20.0 | 22.8 | - | 21.1 | 15.8 | 12.2 | ||||||||||||||||||||||||||||||||||||||||||||||
Contributions by Agency Type - Independent (%) | 50.9 | 44.8 | 44.4 | 47.7 | - | 48.9 | 49.5 | 46.2 | ||||||||||||||||||||||||||||||||||||||||||||||
Contributions by Agency Type - Affiliated (%) | 45.4 | 52.5 | 51.9 | 49.2 | - | 48.0 | 48.4 | 50.2 | ||||||||||||||||||||||||||||||||||||||||||||||
Number of Sales Agencies | 7,300 | 7,200 | 7,100 | 7,000 | - | 7,210 | 7,082 | 6,600 | ||||||||||||||||||||||||||||||||||||||||||||||
Number of Licensed Sales Associates | 110,000 | 113,000 | 113,000 | 113,000 | - | 112,645 | 114,424 | 114,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Agreements to Sell at Banks | 359 | 360 | 360 | 360 | - | 360 | 360 | 360 | ||||||||||||||||||||||||||||||||||||||||||||||
New Money Yield (%) | 5.18 | 4.75 | 4.28 | 6.73 | - | 5.57 | 5.96 | 6.21 | ||||||||||||||||||||||||||||||||||||||||||||||
Return on Average Invested Assets (%) | 2.57 | 2.77 | 3.07 | 3.12 | - | 3.14 | 3.59 | 3.16 | ||||||||||||||||||||||||||||||||||||||||||||||
Portfolio Book Yield (%) | 3.13 | 3.19 | 3.19 | 3.18 | - | 3.24 | 3.32 | 3.21 | ||||||||||||||||||||||||||||||||||||||||||||||
Premium Persistency (%) | 93.9 | 93.8 | 93.5 | 93.4 | - | 93.4 | 93.3 | 93.3 | ||||||||||||||||||||||||||||||||||||||||||||||
Annualized Premiums in Force (¥ Trillion) | ¥1.28 | ¥1.27 | ¥1.26 | ¥1.246 | - | ¥1.23 | ¥1.22 | ¥1.22 | ||||||||||||||||||||||||||||||||||||||||||||||
Weighted-Average DSCR for CMLs | 2.43 | 2.42 | 2.43 | 2.49 | - | 2.30 | 2.34 | 2.50 |
Executive Team
Questions to Ask Management
- With competitors aggressively entering the third sector market in Japan and offering lower-priced products, how does Aflac plan to maintain its market share and profitability without engaging in a price war?
- The TSUMITAS product targets younger customers with less disposable income; how are you addressing the potential challenges of lower profitability and higher lapse rates associated with this demographic?
- Given that your expense ratios in both Japan and the U.S. reached record lows this quarter, but with anticipated increases in promotional spending and unscaled businesses, how sustainable are these expense levels moving forward?
- Considering the increase in your commercial real estate loan watch list to approximately $1 billion and ongoing foreclosures, what is your strategy to mitigate potential risks, and how might further real estate market deterioration impact your financial position?
- The significant boost in net investment income appears driven by tactical asset reallocations and favorable short-term rates; with potential rate cuts on the horizon, how do you plan to sustain this elevated income level in your U.S. dollar portfolio?
Past Guidance
Q3 2024 Earnings Call
- Issued Period: Q3 2024
- Guided Period: N/A
- Guidance: The documents do not contain information about the guidance for Q3 2024 for Aflac Incorporated. Therefore, no specific metrics or periods were guided.
Q2 2024 Earnings Call
- Issued Period: Q2 2024
- Guided Period: N/A
- Guidance:
- Expense Ratios:
- Japan: 19% to 21%, expected to end up in the lower end for the full year .
- U.S.: 38% to 40% for the full year .
- Sales and Growth Initiatives:
- U.S.: Stronger sales push expected in the second half of the year .
- Japan: New product TSUMITAS expected to contribute to sales .
- Persistency: Focus on improving persistency in the U.S. .
- Capital Management: Commitment to maintaining strong capital ratios and liquidity .
- Expense Ratios:
Q1 2024 Earnings Call
- Issued Period: Q1 2024
- Guided Period: FY 2024
- Guidance:
- Sales Guidance:
- U.S.: Stronger performance expected in the latter part of the year .
- Japan: Expects to exceed 2023 sales results .
- Expense Ratio:
- Japan: 19% to 21% for the full year .
- Persistency: Improved by 80 basis points to 78.7% in Q1 2024 .
- Capital and Liquidity:
- SMR above 1,100% in Japan and RBC greater than 650% .
- Liquidity position of $3.7 billion .
- Profit Margins:
- Japan: 32.8% pretax profit margin .
- U.S.: 21% pretax margin .
- Investment Income:
- Japan: Adjusted net investment income up 19.3% .
- U.S.: Adjusted net investment income up 4.6% .
- Sales Guidance:
Q4 2023 Earnings Call
- Issued Period: Q4 2023
- Guided Period: FY 2024
- Guidance:
- Japan Segment:
- Net earned premiums: Decline by 2.5% to 1.5% .
- Benefit ratio: 66% to 68% .
- Expense ratio: 19% to 21% .
- Pretax profit margin: 29% to 31% .
- U.S. Segment:
- Net earned premium growth: 3% to 5% .
- Benefit ratio: 45% to 47% .
- Expense ratio: 38% to 40% .
- Profit margin: 19% to 21% .
- Corporate Segment: No specific numeric guidance provided .
- Japan Segment: